***Background.*** Avibactam is a non-beta lactam beta-lactamase inhibitor, with activity against molecular class A, class C, and some class D beta-lactamase enzymes. The purpose of this study was to evaluate the in vitro activity of ceftazidime in combination with avibactam against a large collection of *Pseudomonas aeruginosa* clinical isolates obtained as part of the CANWARD study (2009-2013).

***Methods.*** From January 2009 to December 2013, inclusive, 12 to 15 sentinel hospitals across Canada submitted clinical isolates from patients attending ERs, medical and surgical wards, hospital clinics, and ICUs (CANWARD). Each center was asked to submit clinical isolates (consecutive, one per patient/infection site) from blood (100 to 165), respiratory (100), urine (25 to 50), and wound (25 to 50) infections. Susceptibility testing was performed using broth microdilution as described by CLSI. Doubling concentrations of ceftazidime were evaluated in combination with a fixed concentration of avibactam (4 µg/mL).

***Results.*** 1825 *P. aeruginosa* clinical isolates were obtained as a part of CANWARD. The antimicrobial susceptibility profile of these isolates is presented in the table.

Two-hundred and fifty-seven isolates (14% of the total) were multidrug-resistant (non-susceptible to at least one antimicrobial from 3 or more classes). Ceftazidime-avibactam demonstrated an MIC of ≤8 µg/mL (ceftazidime susceptibility breakpoint) vs 70.4% of MDR isolates. Further, 67.4% of ceftazidime non-susceptible isolates and 79.9% of meropenem non-susceptible isolates had an MIC of ≤8 µg/mL for ceftazidime-avibactam.

  Antimicrobial             MIC~50~ (µg/mL)   MIC~90~ (µg/mL)   Susceptibility Breakpoint (µg/mL)   \% Susceptible
  ------------------------- ----------------- ----------------- ----------------------------------- ----------------
  Amikacin                  4                 16                ≤16                                 93.0
  Ceftazidime               4                 32                ≤8                                  82.7
  Ceftazidime-Avibactam     2                 8                 Not defined                         No data
  Ciprofloxacin             0.25              4                 ≤1                                  76.7
  Colistin                  1                 2                 ≤2                                  94.6
  Gentamicin                2                 16                ≤4                                  83.0
  Meropenem                 0.5               8                 ≤2                                  82.0
  Piperacillin-Tazobactam   4                 64                ≤16/4                               84.7

***Conclusion.*** The combination of ceftazidime-avibactam demonstrated improved in vitro activity over ceftazidime alone vs *P. aeruginosa* clinical isolates obtained from patients across Canada (4-fold reduction in MIC~90~). Over two-thirds of MDR isolates evaluated were inhibited by ≤8 µg/mL of ceftazidime-avibactam.
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